08/12/2017 00:08:33

Denali Therapeutics Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the pricing of its initial public offering of 13,888,888 shares of its common stock at a price to the public of $18.00 per share. In addition, the underwriters have a 30-day option to purchase up to 2,083,333 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on the NASDAQ Global Select Market on December 8, 2017 under the symbol “DNLI.” The offering is expected to close on December 12, 2017, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Morgan Stanley and J.P. Morgan are acting as joint book-running managers for the offering, and Evercore Group L.L.C. is acting as lead manager for the offering.

The offering is made only by means of a prospectus. When available, a copy of the final prospectus relating to this offering may be obtained from:

Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, fax: 212-902-9316, email: prospectusgroup-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or by email: prospectus-eq_fi@jpmchase.com.

A registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission (“SEC”). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Denali

Denali is a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases. Denali is based in South San Francisco.

CONTACT:

Lizzie Hyland

(646) 495-2706

lhyland@gpg.com

or

Morgan Warners

(202) 295-0124

mwarners@gpg.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Jul
VWS
  Her i sommervarmen har jeg kigget lidt på Vestas kvartalsregnskaber og udviklingen i driftsmargine..
44
10 Jul
 
Normal 0 21 false false false DA X-NONE X-NONE ..
40
13 Jul
DANSKE
Kongsmart og 6212 mødes en dag i himlen..... 6212 siger til Kongsmart.., hvad døde du af.. lettelse...
37
10 Jul
GEN
Jeg synes det er ærgeligt for dem der gerne vil holde overblik over debatten, at man starter en ny t..
32
13 Jul
PNDORA
Ledelsens opgave er at drive og udvikle virksomheden på langsigt, og via dette øge virksomhedens vær..
25
13 Jul
VELO
  Lidt forsimplet, kan man sige; MeltDose-teknologien, sænker typisk koncentrationen af grunstof ”Ta..
15
13 Jul
I:SP500
Det er lavere USD og højere oliepris som begynder at slå igennem på Core inflation tallene. I første..
14
10 Jul
DANSKE
Berlingske indfører censur på Facebook:   En bekendt har fået følgende slettet af Berlingske på Berl..
14
11 Jul
I:DAX
Selvfølgelig betaler USA mest, de er også mest krigsliderlige/sidder på det meste krigsmateriel ( go..
12
13 Jul
E:PROTCT
Jeg har advaret flere gange mod Protector og vi er flere der har advaret mod Alf Invest's regnemetod..
11

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Reva Expands Commercial Access to Fantom With New Distribution Partnership in Italy
2
Bio-on successfully completed the first test phase for the special bioplastic production facility inaugurated on 20 June.
3
CLASS ACTION UPDATE for MRCY and FLKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
4
YouGov poll reveals UK adults are seeking innovative, digital payment experiences from their banks
5
Marine Harvest ASA (OSE:MHG): Q2 2018 Trading update

Buy and sell signals

  • Trend
  • Moneymachine

Latest news


Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 July 2018 20:55:38
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180712.1 - EUROWEB1 - 2018-07-16 21:55:38 - 2018-07-16 20:55:38 - 1000 - Website: OKAY